Mental Health Weekly
June 1, 2026
Valerie A. Canady
A single dose of psilocybin may provide rapid relief for people with major depressive disorder (MDD), with benefits emerging within days and lasting for several weeks, according to a randomized clinical trial published May 15 in JAMA Network Open . Researchers of the study, “Short‐Term and Late‐Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial,” found that...
European Archives of Psychiatry and Clinical Neuroscience
June 1, 2026
Ziping He, Yijie Wang, Jiemin Chen et al.
1 citation
BACKGROUND: Several recent trials indicate positive effects of psilocybin in patients with major depressive disorder. However, questions need to be addressed regarding the relationship between dosage and therapeutic outcomes, such as the recommended dose range and frequency for optimal practice as well as the dose-dependent adverse effects. OBJECTIVE: (1) to assess the effectiveness and...
International Journal of Methods in Psychiatric Research
June 1, 2026
Kurt Stocker, Matthias Hartmann, Frederick S. Barrett et al.
For English, the validated part of Psychedelic Experience Scale (PES48) is a four-factor structure called the Mystical Experience Questionnaire (MEQ30). The other validated part of the PES48 consists of four more factors: two more mystical factors (paradoxicality and connectedness, which together with the MEQ30 form the MEQ40), and two more non-mystical factors (visual experience and...
European Journal of Neuroscience
June 1, 2026
Jenna Houff, Andrew Williams, Obie Allen et al.
Clinical trials suggest that a single dose of psilocybin may be an effective treatment for substance use disorders. Choice impulsivity is a value-based decision-making bias that predicts drug-intake escalation and is commonly associated with substance use disorders. The dorsomedial prefrontal cortex regulates choice impulsivity and is enriched with 5-HT2A receptors that mediate effects of...
Psychedelic Medicine
June 1, 2026
William E Rosa, Stephanie Napolitano, Natalie Mcandrew et al.
Psilocybin shows encouraging outcomes for patients with cancer and major depressive disorder (MDD). However, there is insufficient evidence on the use of evidence-based psychotherapeutic interventions to consistently guide and standardize psilocybin preparation, dosing, and integration. Meaning-centered psychotherapy (MCP) is a manualized, brief psychotherapeutic intervention that enhances...
Journal of Psychedelic Studies
May 29, 2026
Alex P. Hood, Gary R Elkins
Abstract Background and Aims Psilocybin-assisted psychotherapy (PAP) is a novel, transdiagnostic treatment in which the 5-HT2A receptor agonist psilocybin is combined with psychotherapy. Studies to date have evaluated PAP's effects on depression, substance use, and end-of-life adjustment. Relatively less attention has been given to its effects on anxiety symptoms, which are highly comorbid with...
Cell Discovery
May 29, 2026
Gang Pei
Psilocybin has emerged as a transformative, rapid-acting, and long-lasting therapeutic for treatment-resistant depression, with its efficacy rooted in the induction of sustained structural and functional remodeling of mood-regulating neural circuits 1 , 2 . However, the field faces a fundamental mechanistic paradox that defies linear signaling models: psilocin, the bioactive metabolite of...
Journal of Psychopharmacology
May 29, 2026
Kristoffer Brendstrup‐brix, Brice Ozenne, Patrick M. Fisher et al.
Patients with chronic cluster headache (CCH) suffer from poor sleep, which may impact their brain microstructure and parenchymal clearance of waste products. Psilocybin has shown promise for the treatment of CCH and has been linked to increased neuroplasticity with possible influences on brain microstructure. To investigate the effects of psilocybin on sleep, brain water diffusivity, and...
Psychopharmacology
May 28, 2026
Mazen A Atiq, Eli Weisman, Rodrigo B Guerra et al.
Psilocybin is among the serotonergic psychedelics closest to potential FDA approval, with growing evidence of therapeutic benefit across psychiatric conditions. As clinical trials expand, systematic characterization of adverse events (AEs) remains essential. While transient hypertensive responses are well documented, hypotensive events such as neurocardiogenic syncope (NCS) are rarely reported....
European Neuropsychopharmacology
May 28, 2026
L Belinger, Nathalie M. Rieser, Etna Engeli et al.
Maintaining effective blinding is a major methodological challenge in psychedelic research. This study provides a comprehensive evaluation of blinding integrity in 120 healthy volunteers who received either psilocybin, MDMA, or methylphenidate (active placebo) in a double-blind, randomized controlled trial. Using a multi-level assessment incorporating forced-choice substance guesses, certainty...